NCT03543969View on ClinicalTrials.gov

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 14, 2018

Primary Completion Date

December 27, 2024

Study Completion Date

December 31, 2028

Conditions
Melanoma (Skin)Skin CancerSkin MelanomaSkin Carcinoma
Interventions
DRUG

Encorafenib

450 mg encorafenib daily by mouth

DRUG

Binimetinib

45 mg binimetinib daily by mouth

DRUG

Nivolumab

240 mg Nivolumab IV every 2 weeks

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER